Gathering life energy
Caring for human health

OEC    Mail    |

搜索
Search
Stock Code:603520
imgboxbg

History

All categories
/
history

Development Process and Key Milestones

1997

In 1997, Taizhou Xianyuan Medical and Health Products Co., Ltd, the predecessor of Starry Pharm, was established.

2000

■ In 2000, Mr. Hu Jinsheng and Mr. Wu Jinwei worked together and changed its name to Zhejiang Taizhou Starry Pharmaceutical Chemical Co., Ltd., and levofloxacin hydrochloride, its  first left oxygen product, was successfully developed.

2003

■ In 2003, with the approval of Zhejiang Provincial Drug Administration, the company set up a pharmaceutical factory -- Zhejiang Starry Pharmaceutical Co., Ltd. in Xianju Sanqiao

2004

■ In 2004, iohexol products passed GMP certification and obtained the "Drug Production License".

2005

■  In 2005, the company was rated as a high-tech enterprise.

2006

■  In 2006, it was changed to a Sino-foreign joint venture. In November of the same year, the company took 120 mu of land from Xianju County's modern industrial agglomeration area and broke ground to build a new factory building.

2008

■ In 2008, the company moved its administrative center to the new factory area in Yangfu. 

2011

■ In 2011, the shareholding system reform was completed and Starry established.

■ Jiangxi Starry Pharmaceutical Co., Ltd. was established.

2012

■ In 2012, Shanghai Starry Pharmaceutical Co., Ltd. was established.

2015

■ In 2015, Shanghai Jianhe Pharmaceutical Technology Co., Ltd was established.

2016

■ Successful landing in China's A-share market (stock code: 603520).

■ Steyr Investment (Hong Kong) Co., Ltd. was established .

■ Taizhou Steyr International Basketball Club Co., Ltd. was established.

2018

■ Zhejiang Taizhou Haishen Pharmaceutical Co., Ltd. was acquired.

2020

■ The preparation products declared by Shanghai Starry Pharmaceutical Co., Ltd., iopamidol injection, iohexol injection and iodixanol injection, obtained approval for registration from the State Drug Administration, which was the first domestic company to pass the compliance evaluation of the drug.